WHITE RABBIT HARNESSES
THE POWER OF THE BRIGHTEST, BRAVEST SCIENTIFIC MINDS
TO TRANSFORM MENTAL HEALTHCARE RESEARCH AND TREATMENT METHODS.
Mental health problems have risen dramatically in recent decades, now accounting for approximately 7% of the worldwide disease burden, a near-doubling in incidence since 1990. The Lancet Commission Report of 2017 found that mental health disorders could cost the global economy up to US$16 trillion between 2010 and 2030 if these problems remain unaddressed.
We think and act differently to challenge and disrupt the high level systems that dictate our understanding of mental health; driving change in the industry, delivering solutions that are scientifically robust, effective and actionable.
White Rabbit was founded by consultant psychiatrist and entrepreneur Dr Prash Puspanathan; and scientist, med-tech innovator and architectural designer Agnieszka Sekula.
White Rabbit focuses on pioneering groundbreaking research, and fostering it into viable methods, treatments and business models.
Enosis Therapeutics transforms robust psychedelic research into tangible, smart tech solutions that makes psychedelic psychotherapy treatment delivery more reliable, accessible and potent.
The Enosis product suite is, headlined by its flagship, patent pending VR tool for at-home psychedelic integration and an accompanying data repository.
The Spatial Therapeutics (STx) methodology helps practitioners gain novel insights into their patient’s psyches, deepen their patient’s engagement in therapy and infuse the therapy with a sense of discovery.
STx.io provides a patent-pending VR tool to clinicians, educational pathway to become an STx practitioner, and a community hub that shares emerging ideas of spatial mind exploration.
Dr. Prash P is a medical doctor, consultant psychiatrist, and entrepreneur at the forefront of psychedelic-assisted psychotherapy. Alongside his private practice, he works as a psychedelic therapist and researcher at the Clinical Psychedelic Lab at Monash University. As a founding member of Psychedelic Institute Australia, he is a vocal advocate for evidence-based, accessible psychedelic care, and has contributed to leading journals including The Lancet and the Australian & New Zealand Journal of Psychiatry, where he promotes the integration of novel therapies into mainstream psychiatry.
He is the co-founder of Enosis Therapeutics, a company pioneering the fusion of immersive technology and psychedelic therapy. Enosis holds an Australian Innovation Patent for its groundbreaking clinical protocol that integrates Virtual Reality with psychedelic-assisted psychotherapy—an approach that has defined a new frontier in treatment, known as Spatial Therapeutics (STx).
Outside the clinical space, Dr. Prash is also the founder of Caleb & Brown, Australia’s largest personalised cryptocurrency brokerage. The firm was awarded Fintech Startup of the Year in 2018 for bridging traditional financial services with the emerging digital asset economy. His work in fintech reflects a broader mission to challenge outdated systems and design agile, tech-enabled infrastructure across industries.
Dr. Prash holds a Bachelor of Medicine and Bachelor of Surgery (Honours) from Monash University and a Master of Psychological Medicine from the University of Melbourne. In 2018, he was named Young Executive of the Year by the Australian Indian Executive Council for his visionary leadership across medicine and technology.
With a unique ability to straddle the clinical and commercial worlds, Dr. Prash is helping redefine the future of mental health—through innovation, ethical entrepreneurship, and a bold commitment to transformative change.
Agnieszka is a scientist with a background in biomedical engineering, psychology and design. She is currently a PhD candidate at Clinical Psychedelic Lab at Monash University and a co-investigator on a psilocybin study for depression, with the goal to improve outcomes and increase access through a personalised, tech-supported design of PAT. As a scientist at Monash, she investigates mechanisms of novel therapeutics, including psychedelics and VR. As a co-founder of Enosis Therapeutics she developed a novel method of leveraging immersive technology to create an insight-focused approach to mental health treatment, well-being and human optimisation. She conducted the World’s first study on using an immersive therapeutic approach in combination with psychedelics to sustain psycho-emotional change.
Agnieszka has over a decade of experience in science innovation using cutting edge biotech tools, including customised imaging robots, 3D modelling and VR. Her work has led her to innovate medical research all over the world, including forensic medicine in Switzerland, space medicine in Austria and translational science in Singapore.
She is devoted to science outreach, extensively advocating for open-science communication, community led research and outcome transparency, with extensive experience in public speaking and teaching to science and non-science audiences. Her designs have been displayed worldwide, including Shanghai EXPO, Florence Biennale or Austrian Sounds of Space. Her work has been featured in ABC Australia, BBC Science, Mashable and Bloomberg and she produced freelance journaling articles for Psychiatric Times and Przekroj Magazine.
